fenfluramine has been researched along with Delusional Disorder in 1 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Delusional Disorder: Disorder with presentation of a facade of coldness with characteristic pervasive mistrust and suspiciousness of others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study examined the prolactin (PRL), adrenocorticotropin (ACTH) and cortisol responses to the direct DA receptor agonist apomorphine (APO) and the selective 5HT-releasing agent d-fenfluramine (d-FEN) in 20 untreated inpatients with DSM-IV schizophrenia and without a history of suicide attempt, compared to 23 hospitalized healthy controls." | 9.10 | Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests. ( Bailey, P; Crocq, MA; Duval, F; Macher, JP; Mokrani, MC; Monreal, J; Valdebenito, M, 2003) |
| "This study examined the prolactin (PRL), adrenocorticotropin (ACTH) and cortisol responses to the direct DA receptor agonist apomorphine (APO) and the selective 5HT-releasing agent d-fenfluramine (d-FEN) in 20 untreated inpatients with DSM-IV schizophrenia and without a history of suicide attempt, compared to 23 hospitalized healthy controls." | 5.10 | Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests. ( Bailey, P; Crocq, MA; Duval, F; Macher, JP; Mokrani, MC; Monreal, J; Valdebenito, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duval, F | 1 |
| Mokrani, MC | 1 |
| Monreal, J | 1 |
| Bailey, P | 1 |
| Valdebenito, M | 1 |
| Crocq, MA | 1 |
| Macher, JP | 1 |
1 trial available for fenfluramine and Delusional Disorder
| Article | Year |
|---|---|
Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests.
Topics: Adrenocorticotropic Hormone; Adult; Apomorphine; Brief Psychiatric Rating Scale; Diagnosis, Differen | 2003 |